Columbia University

Technology Ventures

Call for Pre-Proposals: Sanofi Innovation Awards (IAwards)

September 15, 2018


Sanofi iAwards program is a multi-institutional academic partnership program designed to collaborate with academic investigators to quickly move promising early stage, disease relevant, innovative research towards the clinic. Seventeen premier academic institutions across North America are currently participating in this program. The academic partners are: Brigham and Women’s Hospital, Columbia University, Johns Hopkins University, Massachusetts General Hospital, Boston Children’s Hospital, University of Pennsylvania, Weill Cornell Medical Center, Stanford University, UCLA, UCSF, New York University, Northeastern university, Children’s Hospital of Philadelphia, Dana Farber Cancer Center, Sinai Health (Toronto), Sunnybrook Health (Toronto) and University Health Network (Toronto). 

Through this program, Sanofi aims to fund innovative and translational research ideas that can contribute to our early stage pipeline and ultimately benefit patients. The selected proposals will receive: 

  • $125,000 research funding (including institutional indirect costs) for 12 months
  • Sanofi scientific expertise and guidance
  • In-kind resources such as reagents, tool compounds, etc. may be provided
  • Successful projects could be converted to SRAs and receive additional funding for 2-3 years

Call for Pre-Proposals:

Sanofi is requesting pre-proposals from academic investigators in the participating institutions in multiple therapeutic areas including, immune-oncology, molecular oncology, immunology & inflammation, rare diseases, neurosciences, diabetes and cardiovascular diseases. In addition, pre-proposals in technology areas including gene therapy, single-cell analysis and biologics development will also be considered.  
A copy of the pre-proposal template is attached and additional information on therapeutic areas of interest is provided below. Only the JSSC and select members of Sanofi and your Institution will have access to your pre-proposal. However, information in the pre-proposal is NOT considered confidential and therefore unpublished information should not be disclosed in the pre-proposal. Proposals with third party collaborators other than those from partner institutions within the iAwards Program will not be considered.  

The completed pre-proposals should be submitted to: The deadline for submission of your pre-proposal is: September 15th, 2018.

Pre-Proposal Criteria:

Proposals are invited for the following therapeutic areas: 

  • New and actionable knowledge about disease relevant targets, pathways and mechanisms
  • Early stage compounds or biologics targeting novel disease mechanisms
  • New models for validating disease relevant targets
  • Technology platforms with the potential to significantly improve drug discovery and development (examples – gene therapy, biologics development)
  • Novel therapeutic modalities
  • Immunology & Inflammation 
  • Rare Diseases 
  • Cardiovascular
  • Neurosciences
  • Immuno-oncology (IO)
  • Molecular Oncology
  • Diabetes
  • Biologics Research

Awards Timeline:

August 1st - Issuance of Request for Pre-Proposal by Institution 

September 15th - Submission of completed Pre-Proposals to Institution 

October 15th - Notification by Sanofi of pre-proposals chosen to be pursued as Detailed Proposals 

November 5th - Completion and submission of Detailed Proposals 

Late November - JSSC meets to review Detailed Proposals 

Early December - Institution informed of JSSC funding decisions